Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma
2012-003672-39Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2014
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in dedifferentiated liposarcoma (DDL) and Liposarcoma, sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Progression-free survival at 12 weeks and Progression-free survival. Started Feb 2014; status: completed.
02
Drugs
cabazitaxel
03
Conditions
dedifferentiated liposarcoma (DDL)Liposarcoma
Beyond the preview
Go deeper on 2012-003672-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003672-39.